Top

BMC Neurology

Published in:

Open Access 01-12-2015 | Research article

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Authors: Edina Silajdžić, Maria Björkqvist, Oskar Hansson

Published in: BMC Neurology | Issue 1/2015

Abstract

Background

Phosphorylcholine is one of the major epitopes of oxidised low density lipoprotein. Low levels of IgM antibodies against phosphorylcholine (anti-PC) are associated with development of myocardial infarction and stroke. It has been shown that patients with Alzheimer’s disease and other dementias have significantly lower serum anti-PC levels compared to controls, suggesting that low levels of atheroprotective anti-PC may play a role in AD and dementia.

Methods

We quantified levels of anti-PC levels using an ELISA in plasma from 176 controls, 125 patients with Alzheimer’s disease, 19 patients with vascular dementia and 63 patients with other dementias.

Results

We observed similar plasma anti-PC levels in controls, patients with Alzheimer’s disease, and other dementias.

Conclusions

Our data suggests that anti-PC is not useful as a biomarker for Alzheimer’s disease.

Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, et al. Innate and acquired immunity in atherogenesis. Nat Med. 2002;8:1218–26.CrossRefPubMed

Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, et al. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest. 1995;96:2322–30.CrossRefPubMedPubMedCentral

Frostegard J. Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. Clin Immunol. 2010;134:47–54.CrossRefPubMed

de la Torre JC. A turning point for Alzheimer’s disease? Biofactors. 2012;38:78–83.CrossRefPubMed

Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology. 2009;72:368–74.CrossRefPubMedPubMedCentral

Biessels GJ, Deary IJ, Ryan CM. Cognition and diabetes: a lifespan perspective. Lancet Neurol. 2008;7:184–90.CrossRefPubMed

Chui HC, Zarow C, Mack WJ, Ellis WG, Zheng L, Jagust WJ, et al. Cognitive impact of subcortical vascular and Alzheimer’s disease pathology. Ann Neurol. 2006;60:677–87.CrossRefPubMedPubMedCentral

Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet. 1997;349:151–4.CrossRefPubMed

Kalaria RN, Akinyemi R, Ihara M. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci. 2012;322:141–7.CrossRefPubMed

10.

Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ. 2001;322:1447–51.CrossRefPubMedPubMedCentral

11.

Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology. 2005;65:545–51.CrossRefPubMedPubMedCentral

12.

Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001;154:635–41.CrossRefPubMed

13.

Mielke MM, Rosenberg PB, Tschanz J, Cook L, Corcoran C, Hayden KM, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology. 2007;69:1850–8.CrossRefPubMed

14.

Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141–5.CrossRefPubMed

15.

Eriksson UK, Sjoberg BG, Bennet AM, de Faire U, Pedersen NL, Frostegard J. Low levels of antibodies against phosphorylcholine in Alzheimer’s disease. J Alzheimers Dis. 2010;21:577–84.PubMed

16.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-III-R. Washington, D.C: American Psychiatric Association; 1987. p. 567. xxix.

17.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.CrossRefPubMed

18.

Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies, Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250–60.CrossRefPubMed

19.

Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl. 2000;59:23–30.PubMed

20.

McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment, Consortium on Dementia with Lewy Bodies. Neurology. 1999;53:902–5.CrossRefPubMed

21.

McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease. Arch Neurol. 2001;58:1803–9.CrossRefPubMed

22.

de Faire U, Su J, Hua X, Frostegard A, Halldin M, Hellenius ML, et al. Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism. J Autoimmun. 2010;34:73–9.CrossRefPubMed

23.

Fiskesund R, Stegmayr B, Hallmans G, Vikstrom M, Weinehall L, de Faire U, et al. Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden. Stroke. 2010;41:607–12.CrossRefPubMed

24.

Gronlund H, Hallmans G, Jansson JH, Boman K, Wikstrom M, de Faire U, et al. Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden. Eur J Cardiovasc Prev Rehabil. 2009;16:382–6.CrossRefPubMed

25.

Sjoberg BG, Su J, Dahlbom I, Gronlund H, Wikstrom M, Hedblad B, et al. Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. Atherosclerosis. 2009;203:528–32.CrossRefPubMed

26.

Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131–44.CrossRefPubMed

27.

Padilla ND, Ciurana C, van Oers J, Ogilvie AC, Hack CE. Levels of natural IgM antibodies against phosphorylcholine in healthy individuals and in patients undergoing isolated limb perfusion. J Immunol Methods. 2004;293:1–11.CrossRefPubMed

Title: Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Authors: Edina Silajdžić
Maria Björkqvist
Oskar Hansson
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Neurology / Issue 1/2015
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-015-0260-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Intravenous immunoglobulin for postpolio syndrome: a systematic review and meta-analysis

Clinical associations between gout and multiple sclerosis, Parkinson’s disease and motor neuron disease: record-linkage studies

Central fever in patients with spontaneous intracerebral hemorrhage: predicting factors and impact on outcome

Trust behavior in Parkinson’s disease: results of a trust game experiment

MS in South Asians in England: early disease onset and novel pattern of myelin autoimmunity

Migraine-specific quality of life questionnaire and relapse of medication overuse headache